Last reviewed · How we verify
Furacin (NITROFURAZONE)
Furacin (NITROFURAZONE) is a small molecule nitrofurazone antibiotic developed by SHIRE, targeting Sterile alpha and TIR motif-containing protein 1. It was FDA approved in 1945 for various urinary tract infections caused by bacteria such as Enterobacter, Escherichia coli, Klebsiella, Staphylococcus Aureus, and Staphylococcus Saprophyticus. As an off-patent medication, Furacin is available from multiple generic manufacturers. Key safety considerations include the potential for allergic reactions and gastrointestinal side effects. Commercially, Furacin is available as a generic medication.
At a glance
| Generic name | NITROFURAZONE |
|---|---|
| Sponsor | Takeda |
| Drug class | nitrofurazone |
| Target | Sterile alpha and TIR motif-containing protein 1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1945 |
Approved indications
- Enterobacter Cystitis
- Enterococcus Urinary Tract Infection
- Escherichia coli urinary tract infection
- Klebsiella cystitis
- Staphylococcus Aureus Urinary Tract Infection
- Staphylococcus Saprophyticus Urinary Tract Infection
Common side effects
Key clinical trials
- Comparison of Pit Picking, Phenol and Combined Pit Picking and Phenol Applications in Pilonidal Sinus Treatment
- Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies
- Efficacy and Safety of Nitrazine in the Treatment of ALS (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
- AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
- Polish Microbiome Map
- Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furacin CI brief — competitive landscape report
- Furacin updates RSS · CI watch RSS
- Takeda portfolio CI